 | |
 Above: levocabastine molecular structureBelow: 3D representation of levocabastine molecule | |
| Clinical data | |
|---|---|
| Trade names | Livostin |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pregnancy category |
|
| Routes of administration | Ophthalmic, intranasal[1] |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C26H29FN2O2 |
| Molar mass | 420.528 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Levocabastine (trade nameLivostin or Livocab, depending on the region) is a selective second-generationH1 receptor antagonist which was discovered atJanssen Pharmaceutica in 1979. It is used for allergicconjunctivitis.[3]
As well as acting as an antihistamine, levocabastine has also subsequently been found to act as a potent and selective antagonist for theneurotensin receptorNTS2, and was the first drug used to characterise the different neurotensin subtypes.[4][5] This has made it a useful tool for the study of this receptor.[6][7][8][9][10]
Thepharmaceutical drugBilina is a combination of Levocabastine,benzalkonium chloride, and other components and is typically used in a 0.5 mg/ml suspension as eye-drops, dispensed in 4ml bottles for the treatment of allergicconjunctivitis or similar allergic ocular conditions. Another formulation is available as anasal spray for the management ofallergic rhinitis.[11][12]
 | Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byadding missing information. |
